The transcription factor NFB is activated by phosphorylation and acetylation and plays important roles in inflammatory and immune responses in the cell. Additionally, posttranslational modification of the NFB p65 subunit by O-linked N-acetylglucosamine (OGlcNAc) has been reported, but the modification site of O-GlcNAc on NFB p65 and its exact function have not been elucidated. In this work, we show that O-GlcNAcylation of NFB p65 decreases binding to IB␣ and increases transcriptional activity under hyperglycemic conditions. Also, we demonstrate that both Thr-322 and Thr-352 of NFB p65 can be modified with O-GlcNAc, but modification on Thr-352, not Thr-322, is important for transcriptional activation. Our findings suggest that site-specific O-GlcNAcylation may be a reason why NFB activity increases continuously under hyperglycemic conditions.
increase NFB transcriptional activity. Additionally, we identify Thr-322 and Thr-352 as O-GlcNAcylation sites in a mutation study and with mass spectrometry analysis. Our data show that an increased amount of O-GlcNAcylation on NFB p65 increases the transcriptional activity of NFB. Furthermore, O-GlcNAcylation on Thr-352 inhibits the interaction between NFB and IB. This O-GlcNAcylated NFB is translocated to the nucleus and has a longer half-life in the nucleus than unmodified protein. This finding may partly answer why NFB is continuously activated in diabetic conditions.
Results

OGA Overexpression-Mediated Down-Regulation of O-GlcNAcylation
Inhibits Hyperglycemia-Induced NFB Activation. We first confirmed that hyperglycemic conditions induced NFB activation in rat VSMCs (22) . To examine NFB-mediated gene regulation, we analyzed the expression of a B-luciferase reporter gene construct under normal glucose (5 mM) and high-glucose (25 mM) conditions. When cells were exposed to high glucose for 24 h, an increased amount of B-luciferase reporter gene expression was observed (Fig. 1A) . At this time point, exposure to high-glucose levels increased levels of O-GlcNAcylation on total protein and NFB p65 (Fig. 1B, 1st and 3rd panels from top); however, O-GlcNAcylation of NFB p50 was not detected (data not shown). Furthermore, expression of vascular cell adhesion molecule 1 (VCAM-1), which is known to be controlled by NFB, increased under high-glucose conditions (Fig. 1B, 5th panel) .
To determine the role of O-GlcNAcylation in hyperglycemiainduced NFB activation, we transfected a vector expressing FLAG-tagged human OGA into VSMCs and found that OGA overexpression reduced hyperglycemia-induced NFB activation as measured by luciferase assays (Fig. 1C) . Also, OGA overexpression decreased the observed hyperglycemia-induced increase in VCAM-1 expression (Fig. 1D, 5th panel) . As expected, OGA overexpression decreased levels of O-GlcNAcylation on total proteins and NFB p65 (Fig. 1D, 1st and 3rd panels). Taken together, these results indicate that an increased amount of O-GlcNAcylation has an important role in hyperglycemiainduced NFB activation.
OGA Overexpression Blocks Hyperglycemia-Induced Reduction in NFB p65-IB␣ Interactions and Hyperglycemia-Induced Nuclear
Translocation of NFB p65. Generally, the phosphorylation, ubiquitination, and proteolytic degradation of IB releases NFB, which can then enter the nucleus, bind to DNA, and activate the transcription of various genes (1) (2) (3) . Therefore, we investigated the expression level of IB, the interaction between NFB and IB, and the nuclear translocation of NFB under high-glucose conditions.
When VSMCs were exposed to high glucose for 24 h, the IB␣ expression level was similar to that found under normal-glucose conditions ( Fig. 2A, 1st panel) . To investigate how high-glucose conditions influence the interaction between IB␣ and NFB, we analyzed the amount of IB␣ that coimmunoprecipitated with NFB p65 and found that the interaction between NFB p65 and IB␣ was decreased dramatically under high-glucose conditions ( Fig. 2 A, 2nd and 3rd panels).
We then investigated how OGA overexpression affects the interaction between NFB p65 and IB␣. Interestingly, OGA overexpression inhibited the hyperglycemia-induced decrease in NFB p65-IB␣ interactions but did not significantly affect total IB␣ levels ( Fig. 2 A, 1st 3 panels) .
Next, we investigated the nuclear translocation of NFB p65 in cells under high-glucose conditions by using immunostaining and immunoblotting. NFB p65 was present primarily in the cytosol of the cells under normal-glucose conditions but was translocated to the nucleus under high-glucose conditions (Fig.  2B) . Interestingly, the translocated NFB p65 was found in the cytosol when FLAG-tagged OGA was transfected into the cells under high-glucose conditions (Fig. 2B) . This observation was confirmed by a Western blotting experiment using nuclear extracts (Fig. 2C) . Therefore, O-GlcNAcylation is involved in hyperglycemia-induced NFB activation by inducing a change in NFB p65-IB␣ interactions, resulting in an increase in the nuclear translocation of NFB p65.
OGT Overexpression-Mediated Up-Regulation of O-GlcNAcylation Increases the Transcriptional Activity of NFB. To investigate the influence of increased intracellular O-GlcNAcylation on NFB activity, we transfected a vector expressing FLAG-tagged human OGT into VSMCs. As expected, OGT overexpression increased levels of total protein and NFB p65 O-GlcNAcylation levels (Fig. 3B, 1st and 3rd panels) . Interestingly, OGT overexpression 2) or high-glucose (lanes 3 and 4) levels for 24 h. The levels of O-GlcNAc, NFB p65, VCAM-1, OGT, and OGA were determined in total cell lysates by immunoblotting (IB; 1st, 2nd, and 5th-7th panels, respectively). NFB p65 immunoprecipitates (IP) obtained from cellular extracts were analyzed by immunoblotting for O-GlcNAc and NFB p65 (3rd and 4th panels, respectively). Actin was included as a loading control (8th panel). (C) VSMCs were cotransfected with the B-luciferase reporter gene plasmid and the plasmid expressing FLAG-tagged human OGA, and incubated for 24 h under normal-or high-glucose conditions. The luciferase activity was measured and normalized to ␤-galactosidase activity, and the data shown represent the mean Ϯ SD (n ϭ 3); * , P Ͻ 0.01 by Student's t test. (D) VSMCs transfected with empty vector (lanes 1 and 3) or that encoding FLAG-tagged OGA (lanes 2 and 4) were exposed to normal-glucose (lanes 1 and 2) or high-glucose (lanes 3 and 4) levels for 24 h. The levels of O-GlcNAc, NFB p65, VCAM-1, OGT, OGA, and FLAG-tagged OGA were determined in total cell lysates by immunoblotting (1st, 2nd, and 5th-8th panels, respectively). NFB p65 immunoprecipitates obtained from the cellular extracts were analyzed by immunoblotting for O-GlcNAc and NFB p65 (3rd and 4th panels, respectively). Actin was included as a loading control (9th panel).
Fig. 2.
OGA overexpression inhibits the reduction in NFB p65-IB␣ interactions and nuclear translocation of NFB p65 under high-glucose conditions. VSMCs were transfected with either vector or a plasmid expressing FLAGtagged OGA and exposed to high glucose for 24 h. (A) Immunoblotting (IB) for NFB p65, IB␣, and FLAG-tagged OGA was performed with an anti-NFB p65 antibody, an anti-IB␣ antibody, and an anti-FLAG antibody (1st, 5th, and 6th panels, respectively). NFB p65 immunoprecipitates (IP) were analyzed for IB␣ and NFB p65 expression by using immunoblotting with the corresponding antibodies (2nd and 4th panels, respectively). Actin was used as a loading control (7th panel). (B) (Upper) VSMCs were immunostained by using antibodies against NFB p65 followed by anti-rabbit Ig covalently conjugated to rhodamine (R) to determine the subcellular localization. (Lower) OGA overexpression was detected with an anti-FLAG antibody conjugated to FITC. The percentages of cells showing NFB p65 localization are derived from at least 150 transfected cells with FLAG-OGA in microscopic fields. (C) Immunoblotting of nuclear or cytosolic extracts of VSMCs by using antibodies against NFB p65 was performed to determine NFB p65 nuclear translocation (1st row). The purity of the nuclear and cytosolic extracts was determined by immunoblotting of histone H2A (nuclear fractions, 2nd row) and ␣-tubulin (cytosolic fractions, 3rd row).
also increased a B-luciferase reporter gene expression (Fig. 3A ) and the expression of VCAM-1 (Fig. 3B, 8th panel) . Furthermore, OGT overexpression inhibited NFB p65-IB␣ interactions (Fig. 3B , 6th and 7th panels) and increased the nuclear translocation of NFB p65 ( Fig. 3 C and D) in a manner similar to that observed under hyperglycemia-induced NFB activation. Interestingly, O-GlcNAcylation of NFB p65 and its transcriptional activity are increased in STZ-induced diabetes in mice [supporting information (SI) Fig. S1 ] (23) . Therefore, these results suggest that an increased amount of O-GlcNAcylation up-regulates NFB transcriptional activity, and O-GlcNAcylation-induced NFB activation is closely involved in diabetes.
O-GlcNAcylation of NFB p65 Occurs at Multiple Sites. To identify O-GlcNAcylated sites on NFB p65, we studied His-tagged NFB p65 C-terminal deletion mutants and site-directed substitution mutants of NFB p65, in which Ser or Thr was changed into Ala, expressed in NFB p65 knockout murine embryo fibroblasts (NFB p65 KO MEFs) (24) (Fig. 4, 1st row) . His-NFB p65 mutant proteins were immunoprecipitated from cells overexpressing OGT with an anti-NFB p65 antibody (Fig. 4,  2nd row) , and O-GlcNAcylation levels were identified with an anti-O-GlcNAc antibody (Fig. 4, 3rd row) . The specificity of O-GlcNAcylation on NFB p65 mutant proteins was confirmed by adding 10 mM GlcNAc during immunoblotting (Fig. 4, 4th  row) . As expected, full-length His-NFB p65 (1-551) was modified with O-GlcNAc, but the modification of truncated His-NFB p65 (1-304) was greatly reduced (Fig. 4, 3rd row) . Therefore, O-GlcNAcylation occurs between amino acids 305 and 551. To map the site further, we tested other truncated constructs and found that O-GlcNAcylation occurred on His-NFB p65 (1-330), but the amount of modification was greatly decreased on His-NFB p65 (1-320) (Fig. 4, 3rd row) . These results show that O-GlcNAcylation occurs on Thr-322 of NFB p65 because this is the only possible modification site in NFB p65 between amino acids 321 and 330.
To test this further, we replaced Thr-322 with Ala and found that the amount of O-GlcNAcylation of His-NFB p65 (1-330) was greatly decreased (Fig. 4, 3rd row) . However, full-length NFB p65 T322A was modified still with O-GlcNAc (Fig. 4, 3rd  row) . Therefore, more deletion constructs were made by using the full-length His-NFB p65 T322A to find additional OGlcNAcylation sites. From this investigation, we found that His-NFB p65 (1-360) T322A was largely modified by OGlcNAc compared with His-NFB p65 (1-330) T322A and His-NFB p65 (1-350) T322A (Fig. 4, 3rd (Fig. 4, 3rd row) . From these results, we conclude that Thr-352 of NFB p65 is modified with O-GlcNAc. Additional O-GlcNAcylation sites other than Thr-322 and Thr-352 may exist because O-GlcNAcylation of the full-length and His-NFB p65 (1-520) proteins occurs despite mutations in the identified sites (T322A/T352A) (Fig. 4, 3rd row) . Also, by using mass spectrometry (25, 26) , we identified that O-GlcNAcylation occurs in peptide 337-360 of NFB p65 (Fig. S2) .
O-GlcNAcylation of NFB p65 on Thr-352, but Not on Thr-322, Is
Important for O-GlcNAc-Induced NFB Transcriptional Activation. We then investigated the functional importance of O-GlcNAcylation on both Thr-322 and Thr-352. We used Thr to Ala substitution mutants of NFB p65 expressed in NFB p65 KO MEFs to rule out endogenous NFB p65 activity (24) . Also, we used OGT overexpression and treatment of cells with O-GlcNAcase inhibitors (STZ and PUGNAc) to increase NFB p65 O-GlcNAcylation. First, we investigated whether the mutations in NFB p65 changed the transcriptional activity of NFB by using the luciferase assay. Plasmids encoding the His-tagged wild-type NFB p65 (His-NFB p65 WT) or NFB p65 containing site-specific Thr to Ala substitution mutations (His-NFB p65 T322A or T352A) were cotransfected with FLAG-tagged IB␣ into NFB p65 KO MEFs. In the case of either His-NFB p65 WT or T322A, O-GlcNAcylation increased B-luciferase reporter gene expression, but in the case of T352A, it did not (Fig.  5A) . Additionally, in an electrophoretic mobility-shift assay (EMSA) experiment using nuclear extracts, O-GlcNAcylation increased the DNA-binding affinity of both His-NFB p65 WT and T322A, but O-GlcNAc did not increase the DNA-binding affinity of T352A (Fig. 5B) .
Next, we examined the interactions between the His-NFB p65 mutants and FLAG-tagged IB␣. When NFB p65 KO cotransfected with the plasmid encoding FLAG-tagged OGT (ϩ) or vector control (Ϫ) and incubated for 24 h under normal glucose conditions. Immunoblotting (IB) for O-GlcNAc, NFB p65, IB␣, VCAM-1, OGT, FLAG-OGT, and OGA was performed with the corresponding antibodies (1st, 2nd, 5th, and 8th-11th panels, respectively). NFB p65 immunoprecipitates (IP) were analyzed for O-GlcNAc, NFB p65, and IB␣ (3rd, 4th, and 6th panels, respectively). Actin was used as a loading control (12th panel). (C) (Upper) VSMCs were immunostained by using antibodies against NFB p65 to determine the subcellular localization. (Lower) OGT overexpression was detected with an anti-FLAG antibody conjugated to FITC. The percentages of cells showing NFB p65 localization are derived from at least 150 transfected cells with FLAG-OGT in microscopic fields. (D) Immunoblotting of nuclear or cytosolic extracts of VSMCs by using antibodies against NFB p65 was performed to determine NFB p65 nuclear translocation (1st and 4th panels) or total levels of NFB p65 (7th panel). The purity of the nuclear and cytosolic extracts was determined by immunoblotting of histone H2A (nuclear fractions, 2nd and 5th panels) and ␣-tubulin (cytosolic fractions, 3rd and 6th panels).
MEFs were cultured in the presence of STZ or PUGNAc or were transfected with a plasmid expressing OGT, interactions between either NFB p65 WT or T322A and FLAG-IB␣ were reduced dramatically, but those between His-NFB p65 T352A and FLAG-IB␣ did not change to the same degree (Fig. 5C ). Under these conditions, the total levels of His-NFB p65 and FLAG-IB␣ did not change, but O-GlcNAcylation on His-NFB p65 was increased dramatically after STZ or PUGNAc treatment or upon OGT transfection (Fig. 5C) .
We then studied the nuclear translocation of His-NFB p65 and its mutated forms by using immunostaining. In the case of either His-NFB p65 WT or T322A, the proteins were translocated into the nucleus under elevated O-GlcNAc conditions, but in the case of His-NFB p65 T352A, most of the protein was not translocated (Fig. 5D) . These results were confirmed with immunoblotting experiments by using an anti-NFB p65 antibody on nuclear extracts (Fig. 5E) . Therefore, O-GlcNAcylation on Thr-352, but not on Thr-322, can inhibit the interaction between NFB p65 and IB␣. Taken together, these results show that inhibition of the interaction between NFB p65 and IB␣ caused by O-GlcNAcylation on Thr-352 of NFB p65 induces the nuclear translocation of free NFB p65, resulting in increased transcriptional activity. Also, these results show that site-specific O-GlcNAcylation can regulate NFB activity in hyperglycemic conditions caused by diabetes.
Discussion
Since the discovery of O-GlcNAcylation (27) , it has been reported that O-GlcNAcylation on Ser or Thr residues plays an important role in the function of nucleocytoplasmic proteins (16) (17) (18) . For example, the activity of transcription factors such as Sp-1 and FoxO1 can be modulated by O-GlcNAcylation (28) (29) (30) (31) , and the stability and activity of p53 are also controlled by O-GlcNAcylation (26) . Although it is known that NFB is O-GlcNAcylated (12) and that this modification is important for T and B lymphocyte activation (19) , the specific sites of modification and the functions are not well understood. In this work, we confirmed that the p65 subunit of NFB is O-GlcNAcylated, and we found that this modification plays an important role in modulating hyperglycemia-induced NFB activation. Furthermore, we also found that O-GlcNAcylation on Thr-352 of NFB p65 interrupts the interaction between NFB and IB␣, which increases the nuclear translocation of O-GlcNAcylated NFB. These observations suggest that O-GlcNAcylation plays an important role in protein-protein interactions. Finally, we showed that an increased amount of O-GlcNAcylation on NFB p65 under hyperglycemic conditions might explain, in part, the transcriptional activation of NFB in STZ-induced type 1 diabetic mice.
In our studies, increased levels of O-GlcNAcylated-NFB p65 were observed in cells under high-glucose conditions and in cells treated with STZ, PUGNAc, or overexpressing OGT, and the interaction between NFB p65 and IB␣ dramatically decreased under these conditions. These results could be caused by OGlcNAcylation on NFB p50 and IB␣, but we could not find any O-GlcNAcylation on these 2 proteins (data not shown). Also, by studying Thr to Ala substitution mutants of NFB p65, we found that O-GlcNAcylation of Thr-352 played a crucial role in the interaction between NFB and IB␣.
As reported, some proteins such as p53 and murine estrogen receptor ␤ are reciprocally modified with O-GlcNAc and Ophosphate (26, 32) . Because NFB p65 is also modified with O-phosphate and this modification plays an important role in modulating its activity (2), it is possible that the changes in O-GlcNAcylation level affect not only its activity but also its phosphorylation states. In our experiments, the phosphorylation level on NFB p65 did not change significantly even though its O-GlcNAcylation level was largely increased by treatment with STZ, PUGNAc, or OGT (Fig. S3) . Also, there are no existing reports of modification of the O-GlcNAcylation sites, Thr-322 and Thr-352, by O-phosphate, and we could not identify any phosphorylation on these sites with MS analysis. Therefore, these results indicate that O-GlcNAcylation on NFB p65 is a key regulator of NFB activation, at least in hyper-OGlcNAcylated states such as hyperglycemic conditions. By using C-terminal deletion and substitution mutants of NFB p65, we identified O-GlcNAcylation of amino acids Thr-322 and Thr-352 of NFB p65, and the modification of 1-12) or substitution mutants (lanes , along with the plasmid encoding FLAG-tagged OGT for 12 h. His-NFB p65 immunoprecipitates (2nd row) were obtained from cellular extracts by using the anti-NFB p65 polyclonal antibody and were analyzed by immunoblotting for O-GlcNAc (3rd row). Total levels of His-NFB p65 mutants in these extracts were examined by using the anti-NFB p65 monoclonal antibody (1st row), and the specificity of O-GlcNAcylation on NFB p65 mutants was confirmed by decreasing the modification via the addition of 10 mM GlcNAc (4th row).
Thr-352 was confirmed with MS analysis. By studying the site-directed mutants, we found that O-GlcNAcylation of NFB p65 on Thr-352, but not on Thr-322, was important for the transcriptional activation of NFB through the inhibition of the interaction between NFB p65 and IB␣. However, it has been reported that the binding domain, or Rel homology domain (RHD), to IB␣ exists in the 300 aa residues at the N terminus of NFB p65 (33, 34) . Interestingly, although Thr-322 is closer to the RHD than Thr-352, O-GlcNAcylation on Thr-352 of NFB p65 decreases the interaction with IB␣, but modification on Thr-322 does not likely influence the interaction. It is possible that the O-GlcNAcylation on Thr-352 is closer to the IB␣-binding site than Thr-322 in a solution state. Therefore, future studies of the 3-dimensional structure of NFB p65 and the modification-induced changes of the interaction with other proteins would be beneficial.
According to previous reports, hyperglycemic conditions induce NFB activation via the degradation of IB␣ in VSMCs, and the degradation occurs in relatively quickly (Ϸ180 min) (22) . However, in our experiments, the nuclear localization of NFB was increased under high-glucose conditions at a relatively later time point (Ϸ24 h), although the level of IB␣ was similar to that observed under normal glucose conditions in our experiments. Moreover, hyperglycemia-induced NFB activation was inhibited by OGA overexpression-induced down-regulation of OGlcNAcylation. Therefore, this observation supports the possibility that O-GlcNAcylation-induced inhibition of NFB-IB␣ interactions is involved in the sustained activation of NFB that is associated with diabetes (35) . Additionally, in the STZinduced diabetic mouse model, we found that NFB p65 OGlcNAcylation largely increased, and less IB␣ was bound to NFB p65 in each organ in diabetic mice compared with normal mice. Furthermore, according to a previous report, NFB activation is involved in complications developed by type 1 or 2 diabetic patients (36) . In fact, NFB was activated dramatically in peripheral blood cells isolated from diabetic nephropathy patients (35) . Therefore, O-GlcNAcylation on p65 of NFB appears to be related to its sustained activation in diabetic conditions and the development of complications in diabetic patients. It is likely that other factors also contribute to the diabetes-associated NFB activation.
In our proposed model, O-GlcNAcylation of the NFB p65 subunit, particularly at Thr-352, induces NFB nuclear translocation through the inhibition of the interaction between NFB plasmids encoding FLAG-tagged IB␣, and plasmids encoding the WT or mutant His-tagged NFB p65 proteins were incubated for 12 h in the absence (control) or presence of STZ or PUGNAc. Nuclear NFB DNA-binding affinity was analyzed by EMSA using 32 P-radiolabeled B-enhancer probes. The supershift assay was examined with antibodies against NFB p65 (rabbit polyclonal). (C) Plasmids encoding His-NFB p65 (WT or mutants) and FLAG-IB␣ were cotransfected into NFB p65 KO MEFs. After a 12-h incubation in the absence (control) or presence of STZ, PUGNAc, or after transfection with the plasmid expressing FLAG-tagged OGT, immunoblotting for NFB p65, IB␣, VCAM-1, OGA, and OGA was performed by using the corresponding antibodies (1st, 2nd, and 7th-9th panels, respectively). NFB p65 WT and mutant proteins were also immunoprecipitated from cell lysates, and the immunoprecipitates were analyzed for IB␣, NFB p65, and O-GlcNAc by using immunoblotting (3rd, 4th, and 6th panels, respectively). Actin was used as a loading control (10th panel). (D) Plasmids encoding His-NFB p65 (WT or mutants) and FLAG-IB␣ were cotransfected into NFB p65 KO MEFs and incubated for 12 h in the absence (control) or presence of STZ or PUGNAc. Immunostaining for NFB p65 was performed to determine the subcellular localization of His-NFB p65 WT and mutants. The table indicates percentage localization in each compartment, and the percentages are derived from at least 200 transfected cells in microscopic fields. (E) NFB p65 KO MEFs were cotransfected with empty vector (EV) or plasmids containing His-NFB p65 (WT or mutants) and FLAG-tagged IB␣, and incubated for 12 h in the presence or absence of STZ, PUGNAc, or transfected with a plasmid expressing FLAG-tagged OGT. Immunoblotting of nuclear or cytosolic extracts by using antibodies against NFB p65 was performed to determine NFB p65 nuclear translocation (1st row). The purity of the nuclear and cytosolic extracts was determined by immunoblotting of histone H2A (nuclear fractions, 2nd row) and ␣-tubulin (cytosolic fractions, 3rd row).
and IB␣, resulting in NFB transcriptional activation (Fig. S4) . We observed that O-GlcNAcylation still occurred on NFB p65 when Thr to Ala substitutions were present at Thr-322 and Thr-352. Just as each phosphorylation of p65 of NFB modulates its activity (2, 37) , it is possible that O-GlcNAcylation on other sites also can modulate NFB activity. Therefore, the effects of O-GlcNAcylation at other sites on NFB activity should be investigated in the future.
Methods
Please see SI Methods for the following detailed methods: (i) cell culture, DNA transfection, and plasmids; (ii) reagents and antibodies; (iii) immunoblotting, immunoprecipitation, and immunostaining; (iv) luciferase assays; (v) EMSA; (vi) mapping O-GlcNAc sites using ESI-MS/MS; and (vii) diabetic mouse models.
